Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Kathrin Tarnanidis"'
Autor:
Nikolaus B. Wagner, Benjamin Weide, Mirko Gries, Maike Reith, Kathrin Tarnanidis, Valerie Schuermans, Charlotte Kemper, Coretta Kehrel, Anne Funder, Ramtin Lichtenberger, Antje Sucker, Esther Herpel, Tim Holland-Letz, Dirk Schadendorf, Claus Garbe, Viktor Umansky, Jochen Utikal, Christoffer Gebhardt
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-10 (2019)
Abstract Background Predicting metastasis in melanoma patients is important for disease management and could help to identify those who might benefit from adjuvant treatment. The aim of this study was to investigate whether the tumor microenvironment
Externí odkaz:
https://doaj.org/article/bdaced2bc15445bbb4dd0a04fba39c24
Autor:
Viktor Umansky, Jochen Utikal, Dirk Schadendorf, Antje Sucker, Philipp Beckhove, Ludmila Umansky, Tim Holland-Letz, Kathrin Tarnanidis, Maike Reith, Ramtin Lichtenberger, Huanhuan Jiang, Alexandra Sevko, Christoffer Gebhardt
Purpose: Immunotherapy with ipilimumab improves the survival of patients with metastatic melanoma. Because only around 20% of patients experience long-term benefit, reliable markers are needed to predict a clinical response. Therefore, we sought to d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14d3d31bd491a7c2ae7944eac4b0de8b
https://doi.org/10.1158/1078-0432.c.6524700
https://doi.org/10.1158/1078-0432.c.6524700
Autor:
Viktor Umansky, Jochen Utikal, Dirk Schadendorf, Antje Sucker, Philipp Beckhove, Ludmila Umansky, Tim Holland-Letz, Kathrin Tarnanidis, Maike Reith, Ramtin Lichtenberger, Huanhuan Jiang, Alexandra Sevko, Christoffer Gebhardt
Frequencies and NO production by moMDSCs (Supplementary Fig.1) and serum eotaxin-1 levels in non-responders and responders (Supplementary Fig.2)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::578304951c90a32797edbfa6ad18d1b4
https://doi.org/10.1158/1078-0432.22461132
https://doi.org/10.1158/1078-0432.22461132
Autor:
Viktor Umansky, Jochen Utikal, Dirk Schadendorf, Antje Sucker, Philipp Beckhove, Ludmila Umansky, Tim Holland-Letz, Kathrin Tarnanidis, Maike Reith, Ramtin Lichtenberger, Huanhuan Jiang, Alexandra Sevko, Christoffer Gebhardt
Serum eotaxin-1 levels detected in patients before Ipi infusion (point 0), after the first (point 1) and second infusion (point 2)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::070e9de5060b11a3b1846f0e42af91fe
https://doi.org/10.1158/1078-0432.22461138
https://doi.org/10.1158/1078-0432.22461138
Autor:
Viktor Umansky, Jochen Utikal, Dirk Schadendorf, Antje Sucker, Philipp Beckhove, Ludmila Umansky, Tim Holland-Letz, Kathrin Tarnanidis, Maike Reith, Ramtin Lichtenberger, Huanhuan Jiang, Alexandra Sevko, Christoffer Gebhardt
Frequencies and NO production by moMDSCs from non-responders (A) and responders (B) after the first infusion of ipilimumab.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11279cf6edde71b3680c3f4941b8ccbb
https://doi.org/10.1158/1078-0432.22461144.v1
https://doi.org/10.1158/1078-0432.22461144.v1
Autor:
Benjamin Weide, Maike Reith, Tim Holland-Letz, Anne Funder, Viktor Umansky, Valerie Schuermans, Jochen Utikal, Mirko Gries, Coretta Kehrel, Christoffer Gebhardt, Kathrin Tarnanidis, Antje Sucker, Charlotte Kemper, Ramtin Lichtenberger, Nikolaus B. Wagner, Esther Herpel, Dirk Schadendorf, Claus Garbe
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-10 (2019)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Background Predicting metastasis in melanoma patients is important for disease management and could help to identify those who might benefit from adjuvant treatment. The aim of this study was to investigate whether the tumor microenvironment-derived
Autor:
Alexandra Sevko, Ludmila Umansky, Jochen Utikal, Christoffer Gebhardt, Antje Sucker, Huanhuan Jiang, Kathrin Tarnanidis, Philipp Beckhove, Viktor Umansky, Dirk Schadendorf, Tim Holland-Letz, Ramtin Lichtenberger, Maike Reith
Publikováno v:
Clinical Cancer Research. 21:5453-5459
Purpose: Immunotherapy with ipilimumab improves the survival of patients with metastatic melanoma. Because only around 20% of patients experience long-term benefit, reliable markers are needed to predict a clinical response. Therefore, we sought to d
Autor:
Maike Reith, Kristian Ikenberg, Helmut Naeher, Jana Eubel, Jochen Utikal, Tim Holland-Letz, Viktor Umansky, Ramtin Lichtenberger, Claus Garbe, Annette Pflugfelder, Benjamin Weide, Coretta Kehrel, Kathrin Tarnanidis, Esther Herpel, Christoffer Gebhardt, Nikolaus B. Wagner, Alexander Enk, Christian Busch
Publikováno v:
International Journal of Cancer. 137:2607-2617
RAGE is a central driver of tumorigenesis by sustaining an inflammatory tumor microenvironment. This study links the soluble forms of RAGE (sRAGE and esRAGE) with clinical outcome of melanoma patients. Moreover, tissue expression of RAGE was analyzed
Autor:
Nikolaus B, Wagner, Benjamin, Weide, Maike, Reith, Kathrin, Tarnanidis, Coretta, Kehrel, Ramtin, Lichtenberger, Annette, Pflugfelder, Esther, Herpel, Jana, Eubel, Kristian, Ikenberg, Christian, Busch, Tim, Holland-Letz, Helmut, Naeher, Claus, Garbe, Viktor, Umansky, Alexander, Enk, Jochen, Utikal, Christoffer, Gebhardt
Publikováno v:
International journal of cancer. 137(11)
RAGE is a central driver of tumorigenesis by sustaining an inflammatory tumor microenvironment. This study links the soluble forms of RAGE (sRAGE and esRAGE) with clinical outcome of melanoma patients. Moreover, tissue expression of RAGE was analyzed
Autor:
Jochen Utikal, Kristian Ikenberg, Maike Reith, Wolf-Henning Gebhardt, Christoffer Gebhardt, Kathrin Tarnanidis, Nikolaus B. Wagner, Coretta Kehrel
Publikováno v:
Cancer Research. 75:805-805
The receptor for advanced glycation end-products (RAGE) is known to act as a central driver of tumorigenesis by sustaining a chronic inflammatory tumor microenvironment. Until to date, RAGE has been exclusively described as a cell surface receptor be